2017
Rifaximin-resistant Clostridium difficile strains isolated from symptomatic patients
Search citation statements
Paper Sections
Select...
16
1
0
0
Citation Types
0
5
0
0
Year Published
2018
2025
Publication Types
Select...
17
Relationship
0
17
Authors
Journals
Cited by 17 publications
(5 citation statements)
References 20 publications
0
5
0
0
“…Reigadas et al demonstrated a similar percentage of resistance to rifaximine during study in 1500 bed hospital. The most dominant ribotype was RT 001 and no correlation between C. difficile resistance to rifampicin and the severity of the infection or its recurrences was found [20].…”
mentioning
confidence: 92%
“…Reigadas et al demonstrated a similar percentage of resistance to rifaximine during study in 1500 bed hospital. The most dominant ribotype was RT 001 and no correlation between C. difficile resistance to rifampicin and the severity of the infection or its recurrences was found [20].…”
mentioning
confidence: 92%
“…The breakpoint for VAN (MIC > 2) was based on the European Antimicrobial Susceptibility Test Committee ( 14 ). The resistance breaking points for RFX (MIC > 32) and FSA (MIC > 0.5) were according to the literature ( 15 ). No resistance breaking points were available for fidaxomicin and tigecycline with specific.…”
Section: Methodsmentioning
confidence: 99%
“…Sequential therapy with a regimen of vancomycin 125 mg four times a day for 10 days, followed by rifaximin 400 mg three times a day for 20 days, can be used in the case of a subsequent recurrence of Clostridium difficile [8]. However, further studies are needed to confirm the efficacy of rifaximin and to clarify the development of drug resistance in Clostridium, particularly ribotype 001 [18].…”
Section: Vancomycinmentioning
confidence: 99%
